Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - Performance obligations (Details)

Revenue - Collaboration Agreement - Performance obligations (Details)	3 Months Ended
	Mar. 31, 2021 USD ($) item
Astellas Collaboration Agreement
Performance obligations
Number of co-development targets	3
Number of independent targets \| item	2
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	$ 64,137,000
Astellas Collaboration Agreement \| Rights granted, first independent target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	15,300,000
Astellas Collaboration Agreement \| Rights granted, second independent target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	15,300,000
Astellas Collaboration Agreement \| Research services and rights granted under the co-exclusive license, first co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	18,500,000
Astellas Collaboration Agreement \| Research services and rights under the co-exclusive license, second co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	7,400,000
Astellas Collaboration Agreement \| Research services and rights under the co-exclusive license, third co-development target
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	7,400,000
GSK Collaboration And License Agreement \| Research services for the third target under the agreement with GSK
Performance obligations
Amount of transaction price allocated to performance obligation that has not been recognized as revenue	$ 237,000